GeneTex
United States (US)

FGF9 antibody [FG9-77]

Cat No. GTX10424

Host Mouse
Clonality Monoclonal
Clone Name FG9-77
Isotype IgG1
Application WB, Dot, ELISA
Reactivity Human, Mouse
APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Dilution
WB Assay dependent
Dot 5 μg/ml
ELISA Assay dependent
Not tested in other applications.

Calculated MW

23 kDa. ( Note )

Positive Control

recombinant human FGF-9

Specificity/Sensitivity

The antibody reacts specifically with recombinant FGF-9. It does not cross-react with human acidic FGF or basic FGF.
PROPERTIES

Form

Liquid

Buffer

0.01M PBS pH7.4

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Antigen Species

Mouse

Immunogen

recombinant mouse FGF-9.

Purification

Purified immunoglobulin

Conjugation

Unconjugated

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Background

The FGF family consists of at least nine members (FGF1 to FGF9), with a 30-50% sequence identity at the amino acid level. All besides FGF8 contain two conserved positions of two cysteine residues. FGF9, also known as glia activating factor (GAF), was initially identified in the culture supernatant of a human glioma cell line as having the capability to promote glial cell proliferation. FGF9 is a heparin binding molecule, which is a glycosylated single polypeptide of 208 amino acids (23-30 kD, depending on rate of glycosylation), with a 30% sequence similarity with other members of the FGF family. The molecule is conserved across species (rat FGF9 is 94% identical to the human molecule). FGF9 has a unique spectrum of activity on cells, and it acts on the central nervous system. Although it has a mitogenic effect on fibroblasts like other FGFs, FGF9 has no effect on human umbilical vein endothelial cells. FGF9 stimulates the proliferation of oligodendrocyte type 2 astrocyte progenitor cells, Balb/c 3T3 fibroblasts and rat pheochromacytoma cell line PC-12. Human FGF9 is oncogenic when transfected into murine fibroblasts. Studies have identified FGF9 expression in brain and kidney. FGF9 binds specifically to FGF receptors 2 and 3, but not to FGF receptors 1 and 4. Like all other FGF ligands, FGF9 requires heparin sulfate for high affinity receptor binding and biological activities.

Database

Research Area